Phaseline

Companies › Myungmoon Pharma.

Myungmoon Pharma.: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 4; Metabolic and endocrine, Gastroenterology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CnU capsule
Magnesium salt of chenodeoxycholic acid and ursodeoxycholic acid
–Phase 4Cholesterol CholelithiasisNov 2027
CnU capsule 500 mg–Phase 4Biliary DyspepsiaNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07005752CnU capsulePhase 4Cholesterol CholelithiasisMetabolic and endocrineNov 2027
NCT07016269CnU capsule 500 mgPhase 4Biliary DyspepsiaGastroenterologyNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Visirna Therapeutics HK Currax Pharmaceuticals Rivus Pharmaceuticals Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.